Point72 Asia Singapore Pte. Ltd. Purchases Shares of 45,520 Ikena Oncology, Inc. (NASDAQ:IKNA)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 45,520 shares of the company’s stock, valued at approximately $75,000.

Several other institutional investors have also made changes to their positions in IKNA. BVF Inc. IL raised its position in Ikena Oncology by 50.5% in the fourth quarter. BVF Inc. IL now owns 4,769,164 shares of the company’s stock worth $9,395,000 after purchasing an additional 1,600,000 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Ikena Oncology by 813.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock worth $729,000 after buying an additional 457,245 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Ikena Oncology in the 4th quarter worth approximately $636,000. Sofinnova Investments Inc. lifted its position in shares of Ikena Oncology by 230.7% during the 2nd quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock worth $631,000 after buying an additional 266,904 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in Ikena Oncology by 1,201.8% in the 1st quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock valued at $400,000 after buying an additional 261,060 shares in the last quarter. 75.00% of the stock is currently owned by institutional investors and hedge funds.

Ikena Oncology Stock Up 1.8 %

NASDAQ:IKNA opened at $1.70 on Friday. The firm has a market cap of $82.04 million, a PE ratio of -1.08 and a beta of 0.49. Ikena Oncology, Inc. has a 12 month low of $1.02 and a 12 month high of $4.63. The company’s 50-day moving average price is $1.69 and its two-hundred day moving average price is $1.57.

Ikena Oncology (NASDAQ:IKNA) last announced its earnings results on Thursday, August 8th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. On average, research analysts expect that Ikena Oncology, Inc. will post -1.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Ikena Oncology in a research note on Monday, August 12th.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.